Find information on common issues.
Ask questions and find answers from other users.
Suggest a new site feature or improvement.
Check on status of your tickets.
Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials. More information on Nanomedicine can be found here.
[Illinois]: CABPN Workshop Nov.7,2012 - Biomaterials, Nanomedicine, Tissue Engineering
Ranking is calculated from a formula comprised of user reviews and usage data. Learn more ›
03 Feb 2013 | Online Presentations | Contributor(s): Jianjun Cheng, NanoBio Node
From the Dept. of Materials Science and Engineering: Our research is focused on design, synthesis, characterization and evaluation of polymeric and nano-structured biomaterials for fundamental …
[Illinois]: BioNanotechnology Seminar Series Fall 2012: Towards the Development of Click Chemistry-Mediated Nanomedicine for Cancer Cell Targeting
17 Dec 2012 | Online Presentations | Contributor(s): Vahid Mirshafiee
Nanoparticulate delivery vehicles for cancer targeting and therapy are routinely prepared by incorporating a targeting ligand, such as an antibody or aptamer, to the surface of nanoparticles. The …
Application of Dynamic Light Scattering in the Physicochemical Characterization of Natural and Engineered Nanoparticles
20 Apr 2012 | Online Presentations | Contributor(s): Trisha Eustaquio
This presentation will highlight the use of dynamic light scattering (DLS), which measures the hydrodynamic size of nanoparticles in suspension, in characterizing specific examples of engineered and …
The Importance of Zeta Potential for Drug/Gene Delivery in Nanomedicine
11 Apr 2012 | Online Presentations | Contributor(s): James Leary
Finding a Needle in a Haystack: Nanobarcoding for Single Nanoparticle Detection in in vitro and ex vivo Nanomedical Biodistribution Studies
14 Feb 2012 | Online Presentations | Contributor(s): Trisha Eustaquio
Determination of the fate of administered nanoparticles in a biological system, or nanoparticle biodistribution, is critical in evaluating a nanoparticle formulation for nanomedical purposes. Unlike …
Illinois Nano EP Seminar Series Spring 2011: Interfacing Engineering, Biology, and Medicine at the Micro and Nano Scale
13 Dec 2011 | Online Presentations | Contributor(s): Rashid Bashir
In this talk, we will present an overview of our work in Silicon-Based BioMEMS and Bionanotechnology and discuss the state of the art and the future challenges and opportunities. We will review a …
KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor
07 Dec 2011 | Online Presentations | Contributor(s): Youngro Byun
Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical application …
KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?
06 Dec 2011 | Online Presentations | Contributor(s): J. Paul Robinson
Outline: Outline the Professors Dilemma Show what the normal criteria for research project direction is Discuss the Corporate perspective Discuss an example of failed innovation Demonstrate …
KIST/PU Designing a Research Program Around Unmet Clinical Needs
06 Dec 2011 | Online Presentations | Contributor(s): Alyssa Panitch
Dr. Panitch specializes in bioorganic chemistry, controlled release and materials and peptide therapeutics. Her research interests include the design and synthesis of biomaterials for drug delivery, …
KIST/PU Theragnosis – A New Paradigm of Personalized Medicine
06 Dec 2011 | Online Presentations | Contributor(s): Ick Chan Kwon
Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in …
Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy
05 Dec 2011 | Online Presentations | Contributor(s): Li Tang
Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for cancer …
Illinois BioNanotechnology Seminar Series Fall 2011: Directed Blood Vessel Growth Using an Angiogenic Microfiber/Microparticle Composite Patch
05 Dec 2011 | Online Presentations | Contributor(s): Ross J DeVolder
Therapeutic angiogenesis has emerged as a promising strategy to treat various acute and chronic vascular diseases, and to enhance tissue repair and regeneration. Common revascularization therapies …
Illinois BioNanotechnology Seminar Series Fall 2011: Deconvolving Stiffness in MEMS Pedestal Cell Mass Measurements
05 Dec 2011 | Online Presentations | Contributor(s): Elise Corbin
The complex relationships between a cell's behavior and the physical properties of both itself and its environment have long been of interest. Specifically, the understanding the mechanisms through …
BME 695L Special Lecture 4: Atomic Force Microscopy (AFM) for Nanomedical Systems (cells and nanoparticles)
02 Dec 2011 | Online Presentations | Contributor(s): Helen McNally
Guest lecturer: Helen McNally
BME 695L Special Lecture 3: In vivo Model Systems to Study Nanomedical Approaches to Cancer Detection and Intervention
02 Dec 2011 | Online Presentations | Contributor(s): Deborah W Knapp
Guest lecturer: Deborah Knapp.
BME 695L Lecture 15: GMP and Issues of Quality Control Manufacture of Nanodelivery Systems
02 Dec 2011 | Online Presentations | Contributor(s): James Leary
See references below for related reading. 15.1 Overview 15.1.1 What does cGMP mean? 15.1.2 Why GMP? Controlling processes means more predictable outcomes… 15.1.3 Enforcement …
BME 695L Lecture 16: FDA and EPA Regulatory Issues
See references below for related reading. 16.1 Introduction and overview 16.1.1 How does the FDA think about nanomedical systems? 16.1.2 The 2006 Nanotechnology Task Force 16.2 …
BME 695L Lecture 12: Assessing Drug Efficacy and Nanotoxicity at the Single Cell Level
22 Nov 2011 | Online Presentations | Contributor(s): James Leary
See references below for related reading. 12.1 Introduction to measures of efficacy for nanomedicine 12.1.1 for evaluation purposes, does structure/size reveal function? 12.1.2 …
BME 695L Lecture 13: Designing Nanomedical Systems (NMS) for In-vivo Use
See references below for related reading. 13.1 Bringing in-vivo considerations into NMS design 13.1.1 the in-vitro to ex-vivo to in-vivo paradigm 18.104.22.168 In-vitro - …
BME 695L Lecture 14: Designing and Testing Integrated Nanomedical Systems
See references below for related reading. 14.1 Introduction to integrated designs 14.1.1 “Total design” but there is some order in the design process 14.1.2 A brief outline of …
nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies.